FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2967434552> ?p ?o ?g. }

• W2967434552 endingPage "1137" @default.
• W2967434552 startingPage "1137" @default.
• W2967434552 abstract "In the absence of identified therapeutic targets, chemotherapy is the main systemic treatment option for triple-negative breast cancer (TNBC). The achievement of a pathological complete response (pCR) after neoadjuvant chemotherapy leads to good outcome, whereas patients not achieving a pCR are at high risk of relapse. Various trials have evaluated the inclusion of platinum in neoadjuvant chemotherapy regimens for TNBC, leading to non-univocal results. The panel of the Italian Association of Medical Oncology (AIOM) Guidelines on Breast Cancer developed a clinical recommendation on the addition of platinum to anthracycline/taxane-based neoadjuvant chemotherapy for TNBC by using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) methodology and the Evidence to Decision framework (EtD). Five studies were eligible. The panel identified the following outcomes of benefit: pCR (critical), disease/event-free survival (DFS/EFS, critical), and overall survival (OS, critical). The panel identified febrile neutropenia (critical), serious adverse events (critical), anemia grade 3-4 (important), thrombocytopenia grade 3-4 (important) as outcomes of harms. The probability of pCR was higher in the platinum-based chemotherapy group versus control group (RR = 1.45, 95%CI 1.28-1.64); however, no impact on long-term outcome was observed. Neoadjuvant treatment regimens containing platinum resulted in a non-significant increase in the risk of febrile neutropenia and in a significant increase in the risk serious adverse events, G3-G4 anemia and G3-G4 thrombocytopenia: 11.3% versus 0.8%, RR = 15.66 (95%CI 6.38-38.44). The panel judged uncertain/favorable the benefit/harms balance. The panel's final recommendation was conditional in favor of the inclusion of platinum in anthracycline/taxane-based neoadjuvant regimens for TNBC." @default.
• W2967434552 created "2019-08-22" @default.
• W2967434552 creator A5000459628 @default.
• W2967434552 creator A5013062135 @default.
• W2967434552 creator A5022206145 @default.
• W2967434552 creator A5023259391 @default.
• W2967434552 creator A5023635155 @default.
• W2967434552 creator A5025190469 @default.
• W2967434552 creator A5030013928 @default.
• W2967434552 creator A5031414207 @default.
• W2967434552 creator A5050421775 @default.
• W2967434552 creator A5051951830 @default.
• W2967434552 creator A5058796036 @default.
• W2967434552 creator A5065261887 @default.
• W2967434552 creator A5068906915 @default.
• W2967434552 creator A5074479074 @default.
• W2967434552 creator A5078485867 @default.
• W2967434552 creator A5080212287 @default.
• W2967434552 creator A5087216533 @default.
• W2967434552 date "2019-08-08" @default.
• W2967434552 modified "2023-10-17" @default.
• W2967434552 title "Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM)" @default.
• W2967434552 cites W1045121760 @default.
• W2967434552 cites W1969346276 @default.
• W2967434552 cites W1993397541 @default.
• W2967434552 cites W2010208073 @default.
• W2967434552 cites W2033624169 @default.
• W2967434552 cites W2075894019 @default.
• W2967434552 cites W2083778750 @default.
• W2967434552 cites W2086064725 @default.
• W2967434552 cites W2096745115 @default.
• W2967434552 cites W2111786429 @default.
• W2967434552 cites W2113382133 @default.
• W2967434552 cites W2114697881 @default.
• W2967434552 cites W2118605519 @default.
• W2967434552 cites W2120252048 @default.
• W2967434552 cites W2128458647 @default.
• W2967434552 cites W2142486051 @default.
• W2967434552 cites W2157285286 @default.
• W2967434552 cites W2295529860 @default.
• W2967434552 cites W2403389346 @default.
• W2967434552 cites W2407210580 @default.
• W2967434552 cites W2472937910 @default.
• W2967434552 cites W2592710921 @default.
• W2967434552 cites W2618058692 @default.
• W2967434552 cites W2734897937 @default.
• W2967434552 cites W2742282063 @default.
• W2967434552 cites W2745905123 @default.
• W2967434552 cites W2782865216 @default.
• W2967434552 cites W2788106879 @default.
• W2967434552 cites W2801956643 @default.
• W2967434552 cites W2807418950 @default.
• W2967434552 cites W2883110447 @default.
• W2967434552 cites W2902859691 @default.
• W2967434552 cites W2939662863 @default.
• W2967434552 cites W2981485737 @default.
• W2967434552 cites W4211123279 @default.
• W2967434552 cites W4239622015 @default.
• W2967434552 doi "https://doi.org/10.3390/cancers11081137" @default.
• W2967434552 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6721549" @default.
• W2967434552 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31398896" @default.
• W2967434552 hasPublicationYear "2019" @default.
• W2967434552 type Work @default.
• W2967434552 sameAs 2967434552 @default.
• W2967434552 citedByCount "19" @default.
• W2967434552 countsByYear W29674345522019 @default.
• W2967434552 countsByYear W29674345522020 @default.
• W2967434552 countsByYear W29674345522021 @default.
• W2967434552 countsByYear W29674345522022 @default.
• W2967434552 countsByYear W29674345522023 @default.
• W2967434552 crossrefType "journal-article" @default.
• W2967434552 hasAuthorship W2967434552A5000459628 @default.
• W2967434552 hasAuthorship W2967434552A5013062135 @default.
• W2967434552 hasAuthorship W2967434552A5022206145 @default.
• W2967434552 hasAuthorship W2967434552A5023259391 @default.
• W2967434552 hasAuthorship W2967434552A5023635155 @default.
• W2967434552 hasAuthorship W2967434552A5025190469 @default.
• W2967434552 hasAuthorship W2967434552A5030013928 @default.
• W2967434552 hasAuthorship W2967434552A5031414207 @default.
• W2967434552 hasAuthorship W2967434552A5050421775 @default.
• W2967434552 hasAuthorship W2967434552A5051951830 @default.
• W2967434552 hasAuthorship W2967434552A5058796036 @default.
• W2967434552 hasAuthorship W2967434552A5065261887 @default.
• W2967434552 hasAuthorship W2967434552A5068906915 @default.
• W2967434552 hasAuthorship W2967434552A5074479074 @default.
• W2967434552 hasAuthorship W2967434552A5078485867 @default.
• W2967434552 hasAuthorship W2967434552A5080212287 @default.
• W2967434552 hasAuthorship W2967434552A5087216533 @default.
• W2967434552 hasBestOaLocation W29674345521 @default.
• W2967434552 hasConcept C121608353 @default.
• W2967434552 hasConcept C126322002 @default.
• W2967434552 hasConcept C143998085 @default.
• W2967434552 hasConcept C2776694085 @default.
• W2967434552 hasConcept C2776802502 @default.
• W2967434552 hasConcept C2777063308 @default.
• W2967434552 hasConcept C2777511904 @default.
• W2967434552 hasConcept C2778292576 @default.
• W2967434552 hasConcept C2778850193 @default.

• next